TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06589284

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silk 0-0 suture covered by chlorhexidine gluconate dressing
Description: The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing
Description: The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
Study: NCT06586125

Intervention type: OTHER
Intervention: Powered Mobility Training
Description: The study procedure aims to observe the partecipants' behaviour while using the Virtual Reality - Power Mobility Program (VR-PMP) simulator applied during Power Mobility Training in clinical practice for 15 sessions. Participants use either semi-immersive mode (laptop screen with VR-PMP simulator) or immersive mode (head-mounted display with VR-PMP simulator). Five out of ten children unable to use conventional VR controllers or alternative access technologies available on the market, use brain-computer interface (BCI) developed specifically for these children to control the VR-PMP simulator.
Study: NCT06602986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TACE
Description: study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima
Study: NCT06603506

Intervention type: OTHER
Intervention: tumour and blood samples
Description: Tumour and blood samples
Study: NCT05006352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral repeating dose
Study: NCT06590623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester (KE)
Description: Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.
Study: NCT06591390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study: NCT06594120

Intervention type: BEHAVIORAL
Intervention: Multimodal rehabilitation with additional work specific training
Description: The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.

Intervention type: BEHAVIORAL
Intervention: Multimodal rehabilitation with additional work specific training
Description: The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
Study: NCT06591949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BETY
Description: The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will be followed up with a home exercise program, and notes will be taken.
Study: NCT06651593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444881
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by Iv
Study: NCT06593626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetazine
Description: Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetazine
Description: Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.
Study: NCT06596863

Intervention type: DIAGNOSTIC_TEST
Intervention: The association of serum uromodulin with DN
Description: Meta analysis of association of serum uromodulin with DKD

Intervention type: DIAGNOSTIC_TEST
Intervention: The association of serum uromodulin with DN
Description: Meta analysis of association of serum uromodulin with DKD

Intervention type: DIAGNOSTIC_TEST
Intervention: The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
Description: DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN

Intervention type: DIAGNOSTIC_TEST
Intervention: The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
Description: DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
Study: NCT06588335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTLA inhibitor (JS004)
Description: BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab:240mg,intravenous infusion, d1, Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
Study: NCT06595888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: X-ray by Computed Tomography
Study: NCT06599333

Intervention type: BEHAVIORAL
Intervention: Adherence to Care
Description: Questionnaire to assess the perception and readiness of patients in Lebanon towards the effectiveness of digital marketing strategies to improve their adherence to medications they take chronically~The following sections will be considered:~* General Characteristics of the Participants~* Medical and medication history~* Assessment of adherence to chronic medications (Likert scale)~* Digital Marketing Strategies to improve adherence to chronic medications (Likert scale)~* Perceived barriers to adopting digital marketing strategies in Lebanon (Likert scale)
Study: NCT05163158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central vs brachial systolic blood pressure targeting
Description: Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central vs brachial systolic blood pressure targeting
Description: Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
Study: NCT06601452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound prescription of Chinese medicine
Description: The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound prescription of Chinese medicine
Description: The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
Study: NCT06595602

Intervention type: DEVICE
Intervention: Artificial intelligence based decision support system (AI-DSS); software
Description: The device is intended for monitoring and recommending ventilator settings, ventilation mode to qualified Intensive Care Unit (ICU) health care professionals (HCP). This is for medical indications that require invasive mechanical ventilation of the respiratory system in the ICU under international / EU guidelines.~The device receives clinical data via the ICU's data integration platform that includes patient physical and demographic data as well as current vital signs, ventilation parameters, blood gas analysis, general blood laboratory reports, fluid balance and medication. Prediction models based on artificial intelligence algorithms are used to deduce therapy suggestions from received data. The algorithm is carried out on a secured cloud platform.
Study: NCT06595173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention
Description: group where therapeutic art activities such as mandala, drawing, third person singular method are applied.~Therapeutic artistic activities within the program (drawing, zentagle, etc.). The program will be implemented in 6 weeks. At the beginning and end of the program, children\&#39;s anxiety and psychological well-being levels will be evaluated.
Study: NCT06538480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-2012
Description: PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
Study: NCT06538896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Nab-Paclitaxel
Description: Tislelizumab, 200mg, intravenous, every 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rankl inhibitor
Description: RANKL inhibitor determined by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
Study: NCT04752618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-STAIR
Description: PCIT+ STAIR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: Non-trauma focused psychotherapy
Study: NCT05472090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT04093297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid Annuloplasty
Description: Patients will undergo repair of tricuspid regurgitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid Annuloplasty
Description: Patients will undergo repair of tricuspid regurgitation
Study: NCT06599489

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery ..operation
Description: sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery ..operation
Description: sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping
Study: NCT03996070

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser therapy
Description: Erbium YAG laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Erbium YAG laser
Study: NCT06705127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy
Study: NCT06704841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music in combination with mindfulness
Description: Participants will attend two in-person sessions per week over two consecutive weeks. Each session will be up to one hour in duration. During each session, participants will engage in a 20-minute guided meditation while listening to instrumental music.
Study: NCT06704789

Intervention type: DEVICE
Intervention: Measurement of brain activity (fNIRS, EEG)
Description: Brain activity assessments are conducted as a single session lasting approximately 60 minutes

Intervention type: DEVICE
Intervention: Measurement of brain activity (fNIRS, EEG)
Description: Brain activity assessments are conducted as a single session lasting approximately 60 minutes

Intervention type: DEVICE
Intervention: Measurement of brain activity (fNIRS, EEG)
Description: Brain activity assessments are conducted as a single session lasting approximately 60 minutes
Study: NCT06706297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama breathing exercise
Description: Normal breathing, focusing on breathing, Alternative Nose Breathing, Cooling Breath, Bee Buzzing Sound, A breathing exercise of 20 minutes in total, consisting of 5 stages: normal breathing and focusing on breathing.
Study: NCT06705777

Intervention type: DRUG
Group type: OTHER
Intervention: Combinations
Description: Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
Study: NCT06705335

Intervention type: OTHER
Intervention: Blood sample
Description: On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.
Study: NCT06705296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Label Deep Brain Stimulation
Description: Patients will receive open label deep brain stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Double blinded Deep Brain Stimulation
Description: Patients will receive double blinded deep brain stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Description: Patients will receive prolonged exposure therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop Deep brain stimulation
Description: Patients will receive closed loop deep brain stimulation
Study: NCT06704490

Intervention type: OTHER
Intervention: Cesarean section
Description: Observational study without intervention
Study: NCT06706089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention
Description: This nurse-led educational intervention included: a) an oral training session regarding glaucoma by the P.I. lasting 15 minutes, b) provision of printed informational material (leaflet) and c) provision of appropriately selected free informational videos from the World Glaucoma Association on the YouTube -online platform. All of the above mentioned educational methods focused on the disease, its treatment and its long-term management. The oral training session took place in an appropriate, quiet and clean area, respecting the patient's privacy. During this process, study participants had the opportunity and time to ask questions and ask for clarifications or additional information.
Study: NCT06706713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109 Capsule
Description: Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
Study: NCT06706635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of App
Description: Full Access to Mobile App

Intervention type: DEVICE
Group type: OTHER
Intervention: Application of App
Description: Full Access to Mobile App
Study: NCT06705517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: The MD emphasizes a plant-based approach, with a high consumption of vegetables, fruits, whole grains, legumes, and nuts, alongside moderate amounts of fish, seafood, and dairy, while limiting meat, particularly red and processed varieties. Olive oil serves as the main fat source in the diet. In the case of this study participants will also be instructed to limit dairy intake, that although traditionally part of the MD, might exacerbate disease symptomatology in PD patients, likely due to the urate lowering effect of dairy.
Study: NCT06704984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Name: WeChat Intervention Based on the IMB Model
Description: A six-week intervention leveraging an online WeChat public account was implemented, integrating the IMB (Information-Motivation-Behavioral Skills) model into its design. Drawing from literature analysis, the intervention plan was structured into three distinct modules: information, motivation, and behavioral skills. The comprehensive intervention encompassed disseminating knowledge on Internet addiction, identifying and avoiding triggers, fostering withdrawal motivation, imparting coping strategies for cravings and challenging situations, enhancing self-efficacy, and facilitating access to personal and social support. Participants who followed the WeChat public account received automated push notifications containing articles or videos every two days. Throughout the intervention period, engagement was monitored by tracking the readership of the sent content through the WeChat public account's backend data.
Study: NCT04965623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial Shunt
Description: Transcatheter treatment of symptomatic left heart failure patients